“Comparing Medicare Advantage And Traditional Medicare: A Systematic Review,” by Rajender Agarwal, John Connolly, Shweta Gupta, and Amol S. Navathe, Health Affairs Quote:  “Medicare Advantage enrollment has almost doubled since 2010 and now accounts for more than a third of all Medicare beneficiaries. We performed a systematic review to compare Medicare Advantage and traditional Medicare on key metrics. Evidence from forty-eight studies showed that in most or all comparisons, Medicare Advantage was associated with more preventive care visits, fewer hospital admissions and emergency department visits, shorter hospital and skilled nursing facility lengths-of-stay, and lower health care spending. Medicare Advantage outperformed
Read More

“Planning For The Peak-65 Generation,” by Jason Fichtner, Advisor Magazine Quote:  “The greatest surge of new retirees in the nation’s history is fast approaching. In a mere three years, the U.S. will have more 65-year-olds than ever before, with more than 10,000 people turning 65 every day, a number that will increase to more than 12,000 a day until the nation reaches its ‘Peak 65’ moment in 2024.  And by 2030, 20 percent of the U.S. population will be age 65 or older, reaching the traditional age associated with retirement as our nation’s retirement system is at risk like never
Read More

“Controversial Alzheimer’s Drug Wins FDA Approval,” by Judy George, MedPageToday Quote:  “The controversial Alzheimer’s treatment aducanumab (Aduhelm) won FDA approval Monday using the accelerated approval pathway. Under this pathway, the agency approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients and there remains some uncertainty about the drug’s clinical benefit.” LTC Comment, Stephen A. Moses, President, Center for Long-Term Care Reform: Kind of a stretch.        
Read More